pancreatic cancer
Alligator Bioscience in phase to start phase III study in 2025
Alligator CEO: "We are on track to secure a partnership"
Soren Bregenholt
Intervju
Powerful data drives Alligator Bioscience forward
Alligator Bioscience has had a successful...
“Unprecedented” Phase II data for Alligator in pancreatic cancer
Alligator Bioscience continues to present compelling Phase II data...
Intervju
Scandion's CEO comments on the positive patent decision in the US
Scandion Oncology's drug candidate SCO-101 is being evaluated in two clinical...
Intervju
Scandion Oncology reports progress in Q2
Scandion Oncology's Q2 report, presented on Wednesday, emphasizes...
Intervju
EU patent gives Scandion extended commercial exclusivity
The European Patent Office (EPO) intends to grant a...
Scandion moves forward with investments in AML
Danish Scandion Oncology continues the year with investments in...
Scandion's CMO comments on progress in PANTAX
Scandion Oncology has achieved the primary goal in...
Intervju
BiBBInstruments wants to revolutionize the diagnostics of pancreatic cancer
Currently, pancreatic cancer is detected far too often in...
Intervju
An exciting year ahead for Scandion Oncology
In 2022, Scandion continued to make progress in...
BiBBInstruments faces an eventful 2023
For medtech company BiBBInstruments, 2022 was a year of...
Intervju